Eligard Stungulyfsstofn og leysir, lausn 22,5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

eligard stungulyfsstofn og leysir, lausn 22,5 mg

recordati industria chimica e farmaceutica s.p.a.* - leuprorelinum acetat - stungulyfsstofn og leysir, lausn - 22,5 mg

Norditropin FlexPro Stungulyf, lausn 5/1,5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin flexpro stungulyf, lausn 5/1,5 mg/ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 5/1,5 mg/ml

Norditropin FlexPro Stungulyf, lausn 15/1,5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin flexpro stungulyf, lausn 15/1,5 mg/ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 15/1,5 mg/ml

Norditropin FlexPro Stungulyf, lausn 10/1,5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin flexpro stungulyf, lausn 10/1,5 mg/ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn - 10/1,5 mg/ml

Norditropin NordiFlex Stungulyf, lausn í áfylltum lyfjapenna 5 mg /1,5 ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 5 mg /1,5 ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 5 mg /1,5 ml

Norditropin NordiFlex Stungulyf, lausn í áfylltum lyfjapenna 15 mg/1,5 ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 15 mg/1,5 ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 15 mg/1,5 ml

Norditropin NordiFlex Stungulyf, lausn í áfylltum lyfjapenna 10 mg/1,5 ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

norditropin nordiflex stungulyf, lausn í áfylltum lyfjapenna 10 mg/1,5 ml

novo nordisk a/s* - somatropinum inn - stungulyf, lausn í áfylltum lyfjapenna - 10 mg/1,5 ml

Firmagon Evrópusambandið - íslenska - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - degarelix - blöðruhálskirtli - innkirtla meðferð - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Ngenla Evrópusambandið - íslenska - EMA (European Medicines Agency)

ngenla

pfizer europe ma eeig - somatrogon - growth and development - sterum og undirstÚku hormÓn og hliÐstÆÐum - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Prid delta Leggangainnlegg 1,55 g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

prid delta leggangainnlegg 1,55 g

ceva santé animale* - progesteronum inn - leggangainnlegg - 1,55 g